BVI 007

Drug Profile

BVI 007

Alternative Names: BVI-007

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator BioVascular
  • Class Small molecules
  • Mechanism of Action Thrombopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myocardial infarction; Stroke
  • Clinical Phase Unknown Essential thrombocythaemia

Most Recent Events

  • 22 Apr 2016 Clinical trials in Essential thrombocythaemia in USA (unspecified route)
  • 22 Apr 2016 Phase I development in Myocardial infarction and Stroke (Prevention) is ongoing in USA
  • 10 Sep 2007 Phase-I clinical trials in Stroke (prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top